Why Grail Could Be the Sleeper Stock Everyone's About to Notice

Ask some people about Grail (NASDAQ: GRAL), and a Monty Python movie will probably come to mind. The innovative pioneer of liquid biopsies (blood tests that can detect cancer) continues to fly under the radar screen for many investors.That's understandable to some extent. After all, Grail is almost a small-cap stock, with a market cap hovering around $2.6 billion. It's easy to ignore or overlook. But could Grail be a sleeper stock everyone's about to notice? Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool